Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Clin Rheumatol ; 39(11): 3365-3371, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32870418

ABSTRACT

OBJECTIVE: To describe the clinical and serological characteristics of patients with SLE who reached a state of sustained remission for more than 10 years in the absence of treatment. METHODS: From a retrospective cohort of 2121 patients, 44 cases with sustained remission (PtRem) were identified and compared with 88 patients whose course has been chronically active (PtAct).The clinical and serological characteristics were analyzed, as well as the treatment of each group at the beginning of the disease and during its evolution. RESULTS: Older age at disease onset was associated with a tendency to reach a state of prolonged remission. These patients also had a higher frequency of thrombocytopenia at the beginning of the disease 34.1% vs 10.2% (p < 0.001). PtAct had a significantly higher initial SLEDAI compared with cases (10.4 ± 5.6 vs 14.1 ± 5.8; p < 0.001). PtRem had a higher initial frequency of anti-ß2 GP1 IgG antibodies. Also, 25% of these patients were serologically active. We did not find differences in the initial treatment between both groups. The accumulated damage measured by SLICC/ACR damage index at the end of the study was significantly less in the patients who remained in prolonged remission. CONCLUSIONS: Although patients with SLE who achieve prolonged remission have some different characteristics at baseline compared with PtAct, it is not possible to identify a characteristic phenotype for the former. Achieving a state of prolonged remission should always be the goal in patients with SLE. Key Points • SLE patients can reach a very prolonged state of remission, free of treatment, including antimalarials, for at least 10 years. • Venous thromboembolism and thrombocytopenia are commonly present in patients that achieved remission. • The presence of serological markers of activity, even after 10 years in remission, is a risk factor for relapse.


Subject(s)
Lupus Erythematosus, Systemic , Aged , Cohort Studies , Humans , Lupus Erythematosus, Systemic/drug therapy , Remission Induction , Retrospective Studies , Severity of Illness Index
2.
Clin Rheumatol ; 39(11): 3525, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32965601

ABSTRACT

The original published version of the above article contained errors in Key Points and Conclusion sections.

3.
Eur J Neurol ; 20(1): 167-72, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22812600

ABSTRACT

BACKGROUND AND PURPOSE: To evaluate the incidence and predictors of ischaemic recurrent stroke and the adverse events of antithrombotic therapy in patients with first intra- or extracranial vertebral artery dissection (VAD) who were treated with aspirin or oral anticoagulation (OA). METHODS: A 21-year database of consecutive patients with confirmed diagnoses of VAD (n = 110, 63% men; mean age 37.9 ± 8.5 years) without intracerebral hemorrhage and who were treated with aspirin or OA were analyzed retrospectively. In all cases, the admission diagnosis was ischaemic stroke. Three groups were defined according to the site of the dissection: (i) extracranial, (ii) intracranial, and (iii) intra-/extracranial. Clinical follow-up was obtained by neurologic examination. Outcome measures were (i) recurrent ischaemic events (ischaemic stroke or transient ischaemic attack) and (ii) intra- and extracranial major bleeding. RESULTS: No difference in age, smoking, or hypertension was found between patients treated with OA (n = 49) and those treated with aspirin (n = 50). Extracranial artery dissection (49%) had preponderance over intracranial (27%) or intra-/extracranial (23%) location. During the follow-up, recurrent ischaemic events were rare (one case). There were no bleeding complications. The treatment that was used did not influence the functional outcome or recanalization. A good functional outcome (modified Rankin score ≤ 2) was observed in 82 patients. CONCLUSIONS: Although this was a non-randomized study, our data suggest that the frequency of recurrent ischaemic stroke in patients with intra- or extracranial VAD is low and most likely independent of the type of antithrombotic treatment.


Subject(s)
Anticoagulants/therapeutic use , Aspirin/therapeutic use , Carotid Artery, Internal, Dissection/drug therapy , Fibrinolytic Agents/therapeutic use , Vertebral Artery Dissection/drug therapy , Adult , Carotid Artery, Internal, Dissection/diagnosis , Databases, Factual/statistics & numerical data , Female , Humans , Longitudinal Studies , Magnetic Resonance Imaging , Male , Middle Aged , Neurologic Examination , Physical Examination , Retrospective Studies , Statistics, Nonparametric , Tomography, X-Ray Computed , Treatment Outcome , Vertebral Artery Dissection/diagnosis
4.
J Neurochem ; 104(1): 279-86, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18005343

ABSTRACT

Brain-derived neurotrophic factor (BDNF), a member of neurotrophin family, enhances synaptic transmission and regulates neuronal proliferation and survival. Both BDNF and its tyrosine kinase receptors (TrkB) are highly expressed in the hippocampus, where an interaction with adenosine A(2A) receptors (A(2A)Rs) has been recently reported. In the present paper, we evaluated the role of A(2A)Rs in mediating functional effects of BDNF in hippocampus using A(2A)R knock-out (KO) mice. In hippocampal slices from WT mice, application of BDNF (10 ng/mL) increased the slope of excitatory post-synaptic field potentials (fEPSPs), an index of synaptic facilitation. This increase of fEPSP slope was abolished by the selective A(2A) antagonist ZM 241385. Similarly, genetic deletion of the A(2A)Rs abolished BDNF-induced increase of the fEPSP slope in slices from A(2A)R KO mice The reduced functional ability of BDNF in A(2A)R KO mice was correlated with the reduction in hippocampal BDNF levels. In agreement, the pharmacological blockade of A(2)Rs by systemic ZM 241385 significantly reduced BDNF levels in the hippocampus of normal mice. These results indicate that the tonic activation of A(2A)Rs is required for BDNF-induced potentiation of synaptic transmission and for sustaining a normal BDNF tone in the hippocampus.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Brain-Derived Neurotrophic Factor/pharmacology , Hippocampus/physiology , Receptor, Adenosine A2A/physiology , Synaptic Transmission/drug effects , Adenosine A2 Receptor Antagonists , Animals , Dose-Response Relationship, Drug , Drug Interactions , Enzyme-Linked Immunosorbent Assay/methods , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , In Vitro Techniques , Mice , Mice, Knockout , Patch-Clamp Techniques/methods , Receptor, Adenosine A2A/deficiency , Triazines/pharmacology , Triazoles/pharmacology
5.
Purinergic Signal ; 3(4): 333-8, 2007 Sep.
Article in English | MEDLINE | ID: mdl-18404446

ABSTRACT

Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, enhances synaptic transmission and regulates neuronal proliferation and survival. Functional interactions between adenosine A(2A) receptors (A(2A)Rs) and BDNF have been recently reported. In this article, we report some recent findings from our group showing that A(2A)Rs regulate both BDNF functions and levels in the brain. Whereas BDNF (10 ng/ml) increased the slope of excitatory postsynaptic field potentials (fEPSPs) in hippocampal slices from wild-type (WT) mice, it was completely ineffective in slices taken from A(2A)R knock-out (KO) mice. Furthermore, enzyme immunoassay studies showed a significant reduction in hippocampal BDNF levels in A(2A)R KO vs. WT mice. Having found an even marked reduction in the striatum of A(2A)R KO mice, and as both BDNF and A(2A)Rs have been implicated in the pathogenesis of Huntington's disease (HD), an inherited striatal neurodegenerative disease, we then evaluated whether the pharmacological blockade of A(2A)Rs could influence striatal levels of BDNF in an experimental model of HD-like striatal degeneration (quinolinic acid-lesioned rats) and in a transgenic mice model of HD (R6/2 mice). In both QA-lesioned rats and early symptomatic R6/2 mice (8 weeks), the systemic administration of the A(2A)R antagonist SCH58261 significantly reduced striatal BDNF levels. These results indicate that the presence and the tonic activation of A(2A)Rs are necessary to allow BDNF-induced potentiation of synaptic transmission and to sustain a normal BDNF tone. The possible functional consequences of reducing striatal BDNF levels in HD models need further investigation.

6.
Pract Odontol ; 10(3): 9-10, 13-4, 16, 1989 Mar.
Article in Spanish | MEDLINE | ID: mdl-2634849

ABSTRACT

At present, laser technology represents an extremely important advance in multiple disciplines, and one that has been particularly favored in medicine, since different types of lasers are used for treating a variety of ailments. The present paper discusses the generalities of the therapeutic laser, as well as its applications in the field of odontology, for the dental surgeon, lasers constitute a valuable aid in his clinical practice, basically as an analgesic, anti-inflammatory or tissue regenerator (scar-forming) device.


Subject(s)
Laser Therapy , Mouth Diseases/therapy , Humans , Trigeminal Neuralgia/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...